Research Snappy
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News
No Result
View All Result
Research Snappy
No Result
View All Result

Allscripts Agrees to Sell Its CarePort Health Business for $1.35 Billion

researchsnappy by researchsnappy
October 16, 2020
in Investment Research
0
Allscripts Agrees to Sell Its CarePort Health Business for $1.35 Billion
400
SHARES
2.4k
VIEWS
Share on FacebookShare on Twitter

October 15, 2020 (Investorideas.com Newswire) Shares of Allscripts Healthcare Solutions traded 30% higher after the company reported it has agreed to sell its CarePort Health business to WellSky Corp. for $1.35 billion.



Allscripts Healthcare Solutions, Inc. (MDRX:NASDAQ) yesterday announced the “execution of a definitive agreement to sell its CarePort Health (CarePort) business to WellSky Corp., a global health and community care technology company.” The company noted that WellSky is owned jointly by TPG Capital and Leonard Green & Partners which it said are two of the largest private equity firms in the world.

Allscripts Healthcare Solutions explained that its CarePort solutions serve hundreds of hospitals and thousands of post-acute care providers. CarePort effectively and efficiently aids these healthcare facilities and providers in coordinating and transitioning patients through the various settings of care.

The company stated that the agreed upon sale price for CarePort is $1.35 billion, which represents a multiple of more than 13 times CarePort’s revenue over the previous 12 months. The firm added further that the $1.35 billion figure is approximately equal to 21 times CarePort’s non-GAAP adjusted EBITDA over the trailing 12 months. Allscripts stated that at present, CarePort’s revenue represents approximately only about 6% of its total consolidated revenues.

The company stated that it anticipates that the transaction will close by year-end 2020, but remains subject to ordinary closing conditions and regulatory approvals. When the transaction is fully completed, the firm stated that the CarePort client base and associates will transition to WellSky. Until that time, the two companies will continue to remain separate and operate independently. Allscripts advised that it plans to utilize the net proceeds after all taxes to invest in its solutions, deleverage its balance sheet and to make significant share repurchases.

Allscripts Healthcare Solutions’ President and CFO Rick Poulton commented, “WellSky is a great company that will provide both an ideal and permanent home for CarePort and its almost 200 team members…This agreement is another all-around win for Allscripts as it unlocks significant value for our shareholders, enables us to increase our focus on our core business and brings our CarePort customers the benefit of continued investment under new and very strong ownership.”

WellSky’s CEO Bill Miller remarked, “Together with CarePort, WellSky will establish new, meaningful connections between historically disparate settings of care. We have the exciting opportunity to bring care coordination to more providers in service of delivering more informed, personalized care…Through this agreement, we’re ensuring our clients have the intelligent technology they need to do right by their patients, collaborate with payers, and succeed in value-based care models. It’s WellSky’s mission to realize care’s potential, and this moves us that much closer to achieving it.”

Allscripts is an IT solutions firm that provides software and services for clinical, financial and operational needs for the healthcare industry. The firm stated that “its innovative solutions connect people, places and data across an Open, Connected Community of Health™.”

Allscripts Healthcare started the day with a market capitalization of around $1.4 billion with approximately 163 million shares outstanding and a short interest of about 10.6%. MDRX shares opened more than 30% higher today at $11.09 (+$2.78, +33.45%) over yesterday’s $8.31 closing price. The stock has traded today between $10.57 and $11.38 per share and is currently trading at $10.86 (+$2.55, +30.69%).

Disclosure:

1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.

2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.

3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

More Info:


Investorideas.com Newswire

This news is published on the Investorideas.com Newswire – a global digital news source for investors and business leaders

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Follow Us on StockTwits

BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

Buy a biotech guest post on Investorideas.com

Previous Post

Survey of riders on UM driverless shuttle shows vast majority trusted it

Next Post

Are you ready for AI engineering within EU data regulations? | 2020-10-16

Next Post
Are you ready for AI engineering within EU data regulations? | 2020-10-16

Are you ready for AI engineering within EU data regulations? | 2020-10-16

Research Snappy

Category

  • Advertising Research
  • Consumer Research
  • Data Analysis
  • Healthcare Research
  • Investment Research
  • News
  • Top Company News

HPIN International Financial Platform Becomes a New Benchmark for India’s Digital Economy

Top 10 Market Research Companies in the world

3 Best Market Research Certifications in High Demand

  • Privacy Policy
  • Terms of Use
  • Antispam
  • DMCA
  • Contact Us

© 2025 researchsnappy.com

No Result
View All Result
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News

© 2025 researchsnappy.com